Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Invest Dermatol

Retrieve available abstracts of 121 articles:
HTML format
Text format



Single Articles


    February 2017
  1. PUIG-BUTILLE JA, Vinyals A, Ferreres JR, Aguilera P, et al
    AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK/ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy.
    J Invest Dermatol. 2017 Feb 7. pii: S0022-202X(17)30115.
    PubMed     Text format     Abstract available


  2. ZHOU Y, Tripathi SV, Rosman I, Ma J, et al
    Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.
    J Invest Dermatol. 2017 Feb 2. pii: S0022-202X(17)30104.
    PubMed     Text format    


    January 2017
  3. TROUSIL S, Chen S, Mu C, Shaw FM, et al
    Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
    J Invest Dermatol. 2017 Jan 28. pii: S0022-202X(17)30052.
    PubMed     Text format     Abstract available


  4. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.
    PubMed     Text format    


    December 2016
  5. ROOS L, Sandling JK, Bell CG, Glass D, et al
    Higher Naevus Count Exhibits A Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.
    J Invest Dermatol. 2016 Dec 16. pii: S0022-202X(16)32787.
    PubMed     Text format     Abstract available


  6. KAWAKAMI A, Fisher DE
    Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    J Invest Dermatol. 2016;136:2342-2344.
    PubMed     Text format     Abstract available


    November 2016
  7. MELAMED RD, Aydin IT, Rajan GS, Phelps R, et al
    Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    J Invest Dermatol. 2016 Nov 24. pii: S0022-202X(16)32663.
    PubMed     Text format     Abstract available


  8. CHIANG NY, Peng YM, Juang HH, Chen TC, et al
    GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated Galpha12/13/RhoA signaling.
    J Invest Dermatol. 2016 Nov 3. pii: S0022-202X(16)32618.
    PubMed     Text format     Abstract available


    October 2016
  9. KOHLI JS, Tolomio E, Frigerio S, Maurichi A, et al
    Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.
    J Invest Dermatol. 2016 Oct 28. pii: S0022-202X(16)32610.
    PubMed     Text format    


    September 2016
  10. LUCARINI V, Buccione C, Ziccheddu G, Peschiaroli F, et al
    Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to improve anti-tumor response against melanoma.
    J Invest Dermatol. 2016 Sep 10. pii: S0022-202X(16)32368.
    PubMed     Text format     Abstract available


  11. RUNGER TM
    Mechanisms of Melanoma Promotion by Ultraviolet Radiation.
    J Invest Dermatol. 2016;136:1751-2.
    PubMed     Text format     Abstract available


    August 2016
  12. FANG S, Vaysse A, Brossard M, Wang Y, et al
    Melanoma expression genes identified through genome-wide association study of Breslow tumor thickness.
    J Invest Dermatol. 2016 Aug 6. pii: S0022-202X(16)32250.
    PubMed     Text format    


  13. MATHEIS F, Heppt MV, Graf SA, Duwell P, et al
    A bifunctional approach of immunostimulation and uPAR inhibition shows potent antitumor activity in melanoma.
    J Invest Dermatol. 2016 Aug 3. pii: S0022-202X(16)32234.
    PubMed     Text format     Abstract available


    July 2016
  14. SHI J, Zhou W, Zhu B, Hyland PL, et al
    Rare germline copy number variations and disease susceptibility in familial melanoma.
    J Invest Dermatol. 2016 Jul 28. pii: S0022-202X(16)32229.
    PubMed     Text format     Abstract available


  15. KUMAR D, Kumar S, Gorain M, Tomar D, et al
    Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis.
    J Invest Dermatol. 2016 Jul 28. pii: S0022-202X(16)32232.
    PubMed     Text format     Abstract available


  16. PAVLOVA O, Fraitag S, Hohl D
    5-hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32124.
    PubMed     Text format     Abstract available


  17. WEIDE B, Schafer T, Martens A, Kuzkina A, et al
    High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32125.
    PubMed     Text format     Abstract available


  18. WANG JY, Jin L, Yan XG, Sherwin S, et al
    Reactive oxygen species dictate the apoptotic response of melanoma cells to TH588.
    J Invest Dermatol. 2016 Jul 14. pii: S0022-202X(16)32104.
    PubMed     Text format     Abstract available


  19. GULATI N, Garcet S, Fuentes-Duculan J, Gilleaudeau P, et al
    Molecular profiling of immune activation associated with regression of melanoma metastases induced by diphencyprone.
    J Invest Dermatol. 2016 Jul 1. pii: S0022-202X(16)32084.
    PubMed     Text format    


    June 2016
  20. PIETROBONO S, Morandi A, Gagliardi S, Gerlini G, et al
    Downregulation of SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival.
    J Invest Dermatol. 2016 Jun 29. pii: S0022-202X(16)32083.
    PubMed     Text format     Abstract available


  21. GIMOTTY PA, Shore R, Lozon N, Whitlock J, et al
    Miscoding of melanoma thickness in SEER: Research and clinical implications.
    J Invest Dermatol. 2016 Jun 25. pii: S0022-202X(16)31960.
    PubMed     Text format    


  22. GREVELING K, Wakkee M, Nijsten T, van den Bos RR, et al
    Epidemiology of lentigo maligna and lentigo maligna melanoma in the Netherlands, 1989 - 2013.
    J Invest Dermatol. 2016 Jun 24. pii: S0022-202X(16)31365.
    PubMed     Text format     Abstract available


  23. LAUSS M, Nsengimana J, Staaf J, Newton-Bishop J, et al
    Consensus of melanoma gene expression subtypes converges on biological entities.
    J Invest Dermatol. 2016 Jun 23. pii: S0022-202X(16)31363.
    PubMed     Text format    


  24. SALTARI A, Truzzi F, Quadri M, Lotti R, et al
    CD271 downregulation promotes melanoma progression and invasion in 3-dimensional models and in zebrafish.
    J Invest Dermatol. 2016 Jun 17. pii: S0022-202X(16)31351.
    PubMed     Text format     Abstract available


  25. CASULA M, Colombino M, Manca A, Caraco C, et al
    Low levels of genetic heterogeneity in matched lymph node metastases from melanoma patients.
    J Invest Dermatol. 2016 Jun 2. pii: S0022-202X(16)31332.
    PubMed     Text format    


    May 2016
  26. NAJITA JS, Swetter SM, Geller AC, Gershenwald JE, et al
    Sex differences in age at primary melanoma diagnosis in a population-based analysis (US Surveillance, Epidemiology, and End Results, 2005-2011).
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31263.
    PubMed     Text format    


  27. WHITEMAN DC, Green AC, Olsen CM
    The relentless rise in the incidence of melanoma in susceptible Australians - Response.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31259.
    PubMed     Text format    


  28. HALABAN R, Krauthammer M
    RASopathy Gene Mutations in Melanoma.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31257.
    PubMed     Text format     Abstract available


  29. CZARNECKI D
    The relentless rise in the incidence of melanoma in susceptible Australians.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31151.
    PubMed     Text format    


  30. YELAMOS O, Merkel EA, Sholl LM, Zhang B, et al
    Non-overlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi.
    J Invest Dermatol. 2016 May 21. pii: S0022-202X(16)31256.
    PubMed     Text format     Abstract available


  31. KAMENISCH Y, Baban TS, Schuller W, von Thaler AK, et al
    UVA-irradiation induces melanoma invasion via enhanced Warburg effect.
    J Invest Dermatol. 2016 May 13. pii: S0022-202X(16)31243.
    PubMed     Text format     Abstract available


  32. POSCH C, Vujic I, Monshi B, Sanlorenzo M, et al
    Searching for the Chokehold of NRAS Mutant Melanoma.
    J Invest Dermatol. 2016 May 7. pii: S0022-202X(16)30881.
    PubMed     Text format     Abstract available


    April 2016
  33. VAN DE NES J, Wrede K, Ringelstein A, Stiller M, et al
    Diagnosing a primary leptomeningeal melanoma by gene mutation signature.
    J Invest Dermatol. 2016 Apr 6. pii: S0022-202X(16)31023.
    PubMed     Text format    


    March 2016
  34. YOULDEN DR, Baade PD, Soyer HP, Youl PH, et al
    Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study.
    J Invest Dermatol. 2016 Mar 23. pii: S0022-202X(16)30930.
    PubMed     Text format     Abstract available


  35. BEAUMONT KA, Hill DS, Daignault SM, Lui GY, et al
    Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells.
    J Invest Dermatol. 2016 Mar 9. pii: S0022-202X(16)30862.
    PubMed     Text format     Abstract available


  36. RAMBOW F, Bechadergue A, Luciani F, Gros G, et al
    Regulation of melanoma progression through the TCF4/miR-125b/NEDD9 cascade.
    J Invest Dermatol. 2016 Mar 8. pii: S0022-202X(16)30857.
    PubMed     Text format     Abstract available


  37. KYPREOU KP, Stefanaki I, Antonopoulou K, Karagianni F, et al
    Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score.
    J Invest Dermatol. 2016;136:690-695.
    PubMed     Text format     Abstract available


    February 2016
  38. WHITEMAN DC, Green AC, Olsen CM
    The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations to 2031.
    J Invest Dermatol. 2016 Feb 19. pii: S0022-202X(16)00488.
    PubMed     Text format     Abstract available


  39. GE R, Liu L, Dai W, Zhang W, et al
    XPA promotes autophagy to facilitate cisplatin resistance in melanoma cells through the activation of PARP1.
    J Invest Dermatol. 2016 Feb 12. pii: S0022-202X(16)00468.
    PubMed     Text format     Abstract available


  40. ROH MR, Gupta S, Park KH, Chung KY, et al
    Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival.
    J Invest Dermatol. 2016 Feb 5. pii: S0022-202X(16)00458.
    PubMed     Text format     Abstract available


  41. LANDSBERG J, Tuting T, Barnhill RL, Lugassy C, et al
    The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis.
    J Invest Dermatol. 2016;136:372-7.
    PubMed     Text format     Abstract available


  42. SZEGEZDI E, Leverkus M
    Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma.
    J Invest Dermatol. 2016;136:362-4.
    PubMed     Text format     Abstract available


  43. HE Y, Hendriks D, van Ginkel R, Samplonius D, et al
    Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5.
    J Invest Dermatol. 2016;136:541-544.
    PubMed     Text format    


  44. ZHANG K, Wong P, Salvaggio C, Salhi A, et al
    Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.
    J Invest Dermatol. 2016;136:464-472.
    PubMed     Text format     Abstract available


  45. VU HL, Rosenbaum S, Capparelli C, Purwin TJ, et al
    MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
    J Invest Dermatol. 2016;136:453-463.
    PubMed     Text format     Abstract available


    January 2016
  46. GUO S, Guo W, Li S, Dai W, et al
    Serum miR-16: a potential biomarker for predicting melanoma prognosis.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00365.
    PubMed     Text format    


  47. PUUJALKA E, Heinz M, Hoesel B, Friedl P, et al
    Opposing roles of JNK and p38 in lymphangiogenesis in melanoma.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00374.
    PubMed     Text format     Abstract available


  48. JACQUELOT N, Roberti MP, Enot DP, Rusakiewicz S, et al
    Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00366.
    PubMed     Text format     Abstract available


  49. TAYLOR NJ, Handorf EA, Mitra N, Avril MF, et al
    Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families.
    J Invest Dermatol. 2016 Jan 28. pii: S0022-202X(16)00355.
    PubMed     Text format    


  50. HACKER E, Olsen CM, Kvaskoff M, Pandeya N, et al
    Histologic and phenotypic factors and MC1R status associated with BRAF, BRAF and NRAS mutations in a community-based sample of 414 cutaneous melanomas.
    J Invest Dermatol. 2016 Jan 22. pii: S0022-202X(16)00351.
    PubMed     Text format     Abstract available


  51. FAN Y, Lee S, Wu G, Easton J, et al
    Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    J Invest Dermatol. 2016;136:339-42.
    PubMed     Text format    


  52. UGUEN A, Talagas M, Marcorelles P, De Braekeleer M, et al
    BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
    J Invest Dermatol. 2016;136:337-8.
    PubMed     Text format    


  53. PATHRIA G, Garg B, Wagner C, Garg K, et al
    RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.
    J Invest Dermatol. 2016;136:264-74.
    PubMed     Text format     Abstract available


  54. INOZUME T, Yaguchi T, Furuta J, Harada K, et al
    Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    J Invest Dermatol. 2016;136:255-63.
    PubMed     Text format     Abstract available


  55. JAYAWARDANA K, Schramm SJ, Tembe V, Mueller S, et al
    Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
    J Invest Dermatol. 2016;136:245-54.
    PubMed     Text format     Abstract available


  56. NAKAHARA T, Oba J, Shimomura C, Kido-Nakahara M, et al
    Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
    J Invest Dermatol. 2016;136:146-53.
    PubMed     Text format     Abstract available


  57. MAHNKE K, Enk AH
    TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
    J Invest Dermatol. 2016;136:9-11.
    PubMed     Text format     Abstract available


    December 2015
  58. BUZAS K, Marton A, Vizler C, Gyukity-Sebestyen E, et al
    Bacterial sepsis increases survival in metastatic melanoma: Chlamydophila pneumoniae induces macrophage polarization and tumor regression.
    J Invest Dermatol. 2015 Dec 29. pii: S0022-202X(15)00328.
    PubMed     Text format    


  59. GEORGE J, Nihal M, Singh CK, Zhong W, et al
    Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma.
    J Invest Dermatol. 2015 Dec 29. pii: S0022-202X(15)00322.
    PubMed     Text format     Abstract available


  60. CHANG GA, Polsky D
    Mutational Heterogeneity in Melanoma: An Inconvenient Truth.
    J Invest Dermatol. 2015;135:2913-8.
    PubMed     Text format     Abstract available


  61. FEDORENKO IV, Wargo JA, Flaherty KT, Messina JL, et al
    BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
    J Invest Dermatol. 2015;135:3115-24.
    PubMed     Text format     Abstract available


  62. MENON DR, Schaider H
    Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.
    J Invest Dermatol. 2015;135:2923-5.
    PubMed     Text format     Abstract available


    November 2015
  63. WHITEMAN DC, Olsen CM
    Melanoma Incidence and Lethality Is Increased Following Solid Organ Transplantation.
    J Invest Dermatol. 2015;135:2560-2.
    PubMed     Text format     Abstract available


    October 2015
  64. INOZUME T, Yaguchi T, Furuta J, Harada K, et al
    Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    J Invest Dermatol. 2015 Oct 12. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  65. PATHRIA G, Garg B, Wagner C, Garg K, et al
    RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.
    J Invest Dermatol. 2015 Oct 8. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  66. CHEN HY, Villanueva J
    Playing Polo-Like Kinase in NRAS-Mutant Melanoma.
    J Invest Dermatol. 2015;135:2352-5.
    PubMed     Text format     Abstract available


  67. ALDAHAN AS, Mlacker S, Shah VV, Samarkandy S, et al
    Cells to Surgery Quiz: October 2015.
    J Invest Dermatol. 2015;135:e18.
    PubMed     Text format    


    September 2015
  68. FAN Y, Lee S, Wu G, Easton J, et al
    Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    J Invest Dermatol. 2015 Sep 24. doi: 10.1038/jid.2015.
    PubMed     Text format    


  69. NAKAHARA T, Oba J, Shimomura C, Kido-Nakahara M, et al
    Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
    J Invest Dermatol. 2015 Sep 15. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  70. JAYAWARDANA K, Schramm SJ, Tembe V, Mueller S, et al
    Identification, Review and Systematic Cross-Validation of MicroRNA Prognostic Signatures in Metastatic Melanoma.
    J Invest Dermatol. 2015 Sep 9. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  71. UGUEN A, Talagas M, Marcorelles P, De Braekeleer M, et al
    BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
    J Invest Dermatol. 2015 Sep 3. doi: 10.1038/jid.2015.
    PubMed     Text format    


  72. WEI E, Miteva M
    September 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
    J Invest Dermatol. 2015;135:e32.
    PubMed     Text format    


    August 2015
  73. KEEGAN TH, Swetter SM, Tao L, Sunwoo JB, et al
    Tumor Ulceration does not Fully Explain Sex Disparities in Melanoma Survival among Adolescents and Young Adults.
    J Invest Dermatol. 2015 Aug 19. doi: 10.1038/jid.2015.
    PubMed     Text format    


  74. ROBBINS HA, Clarke CA, Arron ST, Tatalovich Z, et al
    Melanoma Risk and Survival Among Organ Transplant Recipients.
    J Invest Dermatol. 2015 Aug 13. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  75. HO AW, Tsao H
    Targeted Therapies in Melanoma: Translational Research at Its Finest.
    J Invest Dermatol. 2015;135:1929-33.
    PubMed     Text format    


    July 2015
  76. TANESE K, Hashimoto Y, Berkova Z, Wang Y, et al
    Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.
    J Invest Dermatol. 2015 Jul 16. doi: 10.1038/jid.2015.
    PubMed     Text format    


  77. HUTCHENREUTHER J, Vincent KM, Carter DE, Postovit LM, et al
    CCN2 Expression By Tumor Stroma is Required for Melanoma Metastasis.
    J Invest Dermatol. 2015 Jul 13. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  78. QUAST SA, Steinhorst K, Plotz M, Eberle J, et al
    Sensitization of Melanoma Cells for Death Ligand Trail is Based on Cell Cycle Arrest, Ros Production and Activation of Proapoptotic Bcl-2 Proteins.
    J Invest Dermatol. 2015 Jul 2. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  79. VAN DEN REEK JM, Kievit W, Gniadecki R, Goeman JJ, et al
    Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.
    J Invest Dermatol. 2015;135:e34.
    PubMed     Text format    


  80. JI Z, Erin Chen Y, Kumar R, Taylor M, et al
    MITF Modulates Therapeutic Resistance through EGFR Signaling.
    J Invest Dermatol. 2015;135:1863-72.
    PubMed     Text format     Abstract available


    June 2015
  81. MAIRHOFER DG, Ortner D, Tripp CH, Schaffenrath S, et al
    Impaired gp100-Specific CD8 T Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
    J Invest Dermatol. 2015 Jun 29. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  82. RIVEIRO-FALKENBACH E, Villanueva CA, Garrido MC, Ruano Y, et al
    Intra- and Inter-tumoral Homogeneity of BRAF Mutations in Melanoma Tumors.
    J Invest Dermatol. 2015 Jun 17. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  83. TANESE K, Hashimoto Y, Berkova Z, Wang Y, et al
    Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.
    J Invest Dermatol. 2015 Jun 3. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  84. PHADKE M, Gibney GT, Rich CJ, Fedorenko IV, et al
    XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.
    J Invest Dermatol. 2015 Jun 3. doi: 10.1038/jid.2015.
    PubMed     Text format    


  85. HANDOKO HY, Rodero MP, Muller HK, Khosrotehrani K, et al
    Lack of Evidence from a Transgenic Mouse Model that the Activation and Migration of Melanocytes to the Epidermis after Neonatal UVR Enhances Melanoma Development.
    J Invest Dermatol. 2015 Jun 2. doi: 10.1038/jid.2015.
    PubMed     Text format    


  86. WIEDER SY, Serasinghe MN, Sung JC, Choi DC, et al
    Activation of The Mitochondrial Fragmentation Protein Drp1 Correlates with Braf Melanoma.
    J Invest Dermatol. 2015 Jun 1. doi: 10.1038/jid.2015.
    PubMed     Text format    


    May 2015
  87. LESSARD L, Liu M, Marzese DM, Wang H, et al
    The CASC15 Long Intergenic Non-Coding RNA Locus is Involved in Melanoma Progression and Phenotype-Switching.
    J Invest Dermatol. 2015 May 27. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  88. POSCH C, Cholewa BD, Vujic I, Sanlorenzo M, et al
    Combined Inhibition of MEK and Plk1 has Synergistic Anti-Tumor Activity in NRAS Mutant Melanoma.
    J Invest Dermatol. 2015 May 27. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  89. MUKHERJEE N, Schwan JV, Fujita M, Norris DA, et al
    Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells.
    J Invest Dermatol. 2015 May 7. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available



  90. Pigmentation & melanoma.
    J Invest Dermatol. 2015;135 Suppl 1:S106-13.
    PubMed     Text format    


    April 2015
  91. GAO L, van den Hurk K, Nsengimana J, Laye JP, et al
    Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.
    J Invest Dermatol. 2015 Apr 28. doi: 10.1038/jid.2015.
    PubMed     Text format    


  92. HWANG S, Kim HE, Min M, Raghunathan R, et al
    Epigenetic Silencing of SPINT2 promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.
    J Invest Dermatol. 2015 Apr 24. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  93. FANG XY, Song R, Chen W, Yang YY, et al
    PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.
    J Invest Dermatol. 2015 Apr 21. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  94. FANG S, Wang Y, Chun YS, Liu H, et al
    Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk and Outcomes.
    J Invest Dermatol. 2015 Apr 7. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  95. GELLER AC, Swetter SM, Weinstock MA
    Focus on early detection to reduce melanoma deaths.
    J Invest Dermatol. 2015;135:947-9.
    PubMed     Text format     Abstract available


  96. GRAY ES, Reid A, Bowyer S, Calapre L, et al
    Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
    J Invest Dermatol. 2015 Apr 1. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  97. KHALIFIAN S, Raimondi G, Brandacher G
    The use of luminex assays to measure cytokines.
    J Invest Dermatol. 2015;135:e31.
    PubMed     Text format    


  98. SIMMONS BJ, Bray FN, Falto-Aizpurua L, Alsaidan M, et al
    Cells to surgery quiz: April 2015.
    J Invest Dermatol. 2015;135:e12.
    PubMed     Text format    


  99. KATIYAR SK
    Hsp90 inhibitor can inhibit UV carcinogenesis.
    J Invest Dermatol. 2015;135:945-7.
    PubMed     Text format     Abstract available


    March 2015
  100. YAZAWA EM, Geddes-Sweeney JE, Cedeno-Laurent F, Walley KC, et al
    Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential.
    J Invest Dermatol. 2015 Mar 10. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  101. SHAO Y, Le K, Cheng H, Aplin AE, et al
    NFkappaB-Regulation of c-FLIP Promotes TNFalpha-Mediated RAF Inhibitor Resistance in Melanoma.
    J Invest Dermatol. 2015 Mar 9. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  102. DAVAR D, Lin Y, Kirkwood JM
    Unfolding the mutational landscape of human melanoma.
    J Invest Dermatol. 2015;135:659-62.
    PubMed     Text format     Abstract available


  103. ZHENG B, Fisher DE
    Metabolic Vulnerability in Melanoma: A ME2 (Me Too) Story.
    J Invest Dermatol. 2015;135:657-9.
    PubMed     Text format     Abstract available


  104. BRAY FN, Simmons BJ, Griffith RD, Falto-Aizpurua L, et al
    Cells to surgery quiz: March 2015.
    J Invest Dermatol. 2015;135:e11.
    PubMed     Text format    


  105. MATSUI MS, Petris MJ, Niki Y, Karaman-Jurukovska N, et al
    Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking.
    J Invest Dermatol. 2015;135:834-41.
    PubMed     Text format     Abstract available


    February 2015
  106. LAUSS M, Haq R, Cirenajwis H, Phung B, et al
    Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
    J Invest Dermatol. 2015 Feb 23. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  107. NUGENT JS, Vince R, Raza A
    Topical Acyclothymidine Dinucleosides (aTds) Promote non-UV Mediated Endogenous Defense Mechanisms in Guinea Pig Skin.
    J Invest Dermatol. 2015 Feb 20. doi: 10.1038/jid.2015.
    PubMed     Text format    


  108. MARRANCI A, Tuccoli A, Vitiello M, Mercoledi E, et al
    Identification of BRAF 3'UTR Isoforms in Melanoma.
    J Invest Dermatol. 2015 Feb 16. doi: 10.1038/jid.2015.
    PubMed     Text format    


  109. ARMSTRONG JL, Hill DS, McKee CS, Hernandez-Tiedra S, et al
    Exploiting Cannabinoid-Induced Cytotoxic Autophagy to Drive Melanoma Cell Death.
    J Invest Dermatol. 2015 Feb 10. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  110. SLIPICEVIC A, Herlyn M
    KIT in Melanoma: Many Shades of Gray.
    J Invest Dermatol. 2015;135:337-8.
    PubMed     Text format     Abstract available


  111. GRIEWANK KG, Schadendorf D
    Panel sequencing melanomas.
    J Invest Dermatol. 2015;135:335-6.
    PubMed     Text format     Abstract available


    January 2015
  112. SNEDECOR ER, Sung C, Moncayo A, Rothstein BE, et al
    Loss of Primary Cilia in Melanoma Cells is Likely Independent of Proliferation and Cell Cycle Progression.
    J Invest Dermatol. 2015 Jan 28. doi: 10.1038/jid.2015.
    PubMed     Text format    


  113. ZHAN Y, Dahabieh MS, Rajakumar A, Dobocan MC, et al
    The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma.
    J Invest Dermatol. 2015 Jan 23. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  114. KHOSRAVI S, Tam KJ, Ardekani GS, Martinka M, et al
    eIF4E is an Adverse Prognostic Marker of Melanoma Patient Survival by Increasing Melanoma Cell Invasion.
    J Invest Dermatol. 2015 Jan 6. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


    December 2014
  115. OLSEN CM, Neale RE, Green AC, Webb PM, et al
    Independent validation of six melanoma risk prediction models.
    J Invest Dermatol. 2014 Dec 30. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


  116. KUMAR R, Taylor M, Miao B, Ji Z, et al
    BAP1 Plays a Survival Role in Cutaneous Melanoma.
    J Invest Dermatol. 2014 Dec 18. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


    November 2014
  117. ANTONOPOULOU K, Stefanaki I, Lill CM, Chatzinasiou F, et al
    Updated Field Synopsis and Systematic Meta-Analyses of Genetic Association Studies in Cutaneous Melanoma: The MelGene Database.
    J Invest Dermatol. 2014 Nov 19. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


  118. SHEEN YS, Liao YH, Lin MH, Chu CY, et al
    IMP-3 Promotes Migration and Invasion of Melanoma Cells by Modulating the Expression of HMGA2 and Predicts Poor Prognosis in Melanoma.
    J Invest Dermatol. 2014 Nov 7. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


  119. OLLAGUE JE, Kirsner RS
    JID VisualDx Quiz: November 2014.
    J Invest Dermatol. 2014;134:e22.
    PubMed     Text format    


    October 2014
  120. SINGH A, Singh A, Sand JM, Bauer SJ, et al
    Topically Applied Hsp90 Inhibitor 17AAG Inhibits Ultraviolet Radiation-Induced Cutaneous Squamous Cell Carcinomas.
    J Invest Dermatol. 2014 Oct 22. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


  121. LEHRAIKI A, Abbe P, Cerezo M, Rouaud F, et al
    Inhibition of melanogenesis by the antidiabetic metformin.
    J Invest Dermatol. 2014;134:2589-97.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: